Global Kinetics Corporation Ltd. today announced the publication of a study evaluating the clinical utility of objective treatment targets derived from its wearable FDA-cleared technology, the Personal KinetiGraph™ (PKG™) smart watch, in the treatment and management of Parkinson’s disease (PD).

Read more on CentralCharts here.